![](/img/cover-not-exists.png)
475 Consistent progression-free survival benefit of capecitabine-bevacizumab in all prespecified subgroups of the RIBBON-1 study in patients with metastatic breast cancer (MBC)
J. O'Shaughnessy, V. Dieras, S. ChanVolume:
8
Year:
2010
Language:
english
DOI:
10.1016/s1359-6349(10)70496-1
File:
PDF, 44 KB
english, 2010